According to a recent study titled ‘Japan Cancer Vaccines Market Share, Size, Trends, Industry Analysis Report, By Vaccine Type; By Indication; By Patient Type; Segments Forecast, 2020 - 2026’, available with Market Study Report, Japan cancer vaccines market is projected to record an appreciable growth rate during 2020-2026 and accumulate a net worth of USD 1,470.4 million by the end of the forecast period.
 

As per the findings of report, Japan cancer vaccines market is primarily driven by the surging number of cancer cases in the nation. According to the National Cancer Registry system, approximately 995,132 new cancer cases were recorded in 2016, of which 428,499 were women and 566,575 were men. This spike in cases has encouraged focus towards preventive care. Although the population follows a low-fat diet that has proven to be effective, the high salt content in Japanese diet is responsible to numerous stomach cancer cases in the nation.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/2963807/
 

Government initiatives aimed at spreading awareness and increasing number of R&D activities are further strengthening Japan cancer vaccines industry outlook. For instance, the University of Tokyo, in Jan 2018, signed an agreement with Kanagawa Cancer Center and BrightPath Biotherapeutics for development of personalized cancer vaccines. Moreover, in a bid to advance regenerative medicine and cell therapy, the Japanese government passed the Act on Safety of Regenerative medicine and the Revised Pharmaceutical Affairs Law in November 2014. 
 

Besides, increasing prevalence of Human Papilloma Virus (HPV) infections that generally lead to cancer is a major growth impetus for cancer vaccines market in Japan. HPV vaccines were added to the national vaccine program in 2013. However, several side effects were reported the same year due to which the recommendation and usages was restricted, and formulations needed to be altered accordingly.  Hence, the time-intensive process along with high cost of development and initial setup are restricting the expansion of Japan Cancer vaccines market.
 

Key players operating in Japan cancer vaccine market are Regeneus Ltd., OncoTherapy Science, Inc., ImmunoFrontier, Inc., Boston Biomedical, Inc. (acquired by DSP Co. Ltd.), Takara Bio, Inc., Takeda Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Daiichi Sankyo Company Ltd., BrightPath Biotherapeutics Co. Ltd., Cytlimic, Oncolys BioPharma, Inc., Tella Inc., Merck & Co. Inc., GSK plc, Bristol-Myers Squibb, AstraZeneca plc, Astellas Pharma, Inc., and Aduro BioTech, Inc.